ReviewFrontiers in immunology2026
The role of protein lactylation in skin diseases: from molecular mechanisms to potential therapeutics.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactylation represents a novel post-translational modification originating from lactate, a by-product of glycolysis. It has emerged as a pivotal mechanism linking cellular metabolism to epigenetic regulation. By transferring the lactyl group to lysine residues on both histone and non-histone proteins, this modification regulates gene transcription and protein function, thereby coordinating critical biological processes, including metabolic reprogramming and immune-inflammatory responses. Recent studies have highlighted the pivotal role of lactate and lactylation in the pathogenesis of diverse skin diseases, including immune-inflammatory skin diseases (e.g., psoriasis and atopic dermatitis), pathologic scars, skin malignancies (e.g., melanoma), and skin ageing. In certain diseases, such as psoriasis and melanoma, lactylation has been established as a core molecular mechanism, establishing a pathological link between systemic metabolic disorders, the local skin microenvironment, immune inflammatory processes, and skin diseases. In other conditions, lactate-mediated effects have been well documented, while the specific contribution of lactylation remains an active area of investigation. Currently, lactylation-related inhibitors have demonstrated therapeutic potential in cancer, metabolic, and immunological fields. Consequently, lactate-mediated lactylation may emerge as a novel therapeutic intervention target for skin disorders. In this review, we summarize recent advances in lactylation research in skin diseases and elucidate its potential as a therapeutic target for future clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.